Elekta Stock - analyst views and technical picture on a quiet news day
18.06.2026 - 20:31:41 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 18:30 UTC. Details in the imprint.
Elekta (SE0000163628) remains without a new corporate announcement or major market-moving headline today. Instead, the stock is shaped by existing analyst recommendations, recent valuation levels and a technical setup that investors continue to monitor.
Background and price data on Elekta stock
Key figures, news and price history help investors understand how Elekta stock trades on its home market in Stockholm and via international listings.
What recent data show
On the Stockholm exchange, Elekta shares most recently closed around SEK 48, giving the company a mid-cap valuation in the European medtech space. The ADR listing in the US traded near $5.02 today, illustrating the currency translation of the Swedish quote.
Swedish business weekly Affärsvärlden recently reiterated a patient stance toward the stock, highlighting an average analyst target price of roughly SEK 60.50 compared with the latest close near SEK 48.16, implying upside from current levels.
Chart picture and volatility
Elekta’s primary listing in Stockholm has been trading in a broad range in recent months, with the shares moving between the low-40s and low-50s SEK, according to recent market data. This range reflects a period of consolidation after earlier weakness in the medtech sector.
On technical indicators, the ADR chart shows the price fluctuating in a narrow band today, between $5.02 and $5.10, suggesting muted intraday volatility and limited directional conviction at this point. For many chart watchers, such tight ranges often precede stronger moves when new information emerges.
Analyst sentiment and valuation
The average target price near SEK 60.50 signals that covering analysts still see Elekta as undervalued versus their fundamental models. However, the range of views remains broad, with some research houses more cautious amid competition and capital-spending cycles at hospital customers.
Against that backdrop, investors are weighing the company’s installed base, recurring software and service revenues, and the potential for margin improvement as management executes on efficiency and product-mix initiatives discussed in recent results presentations.
How Elekta makes money
Elekta generates most of its revenue from oncology-related medical technology, including its flagship linear accelerator systems and associated software for radiation therapy in cancer treatment. The company also earns recurring income from maintenance, upgrades and long-term service agreements with clinics worldwide.
Where the stock trades today
The shares of Elekta (SE0000163628) trade on Nasdaq Stockholm at approximately SEK 48.16 as of 06/18/2026, 17:30 CET.
Key facts on Elekta stock
- Company: Elekta AB
- ISIN: SE0000163628
- WKN: 894682
- Ticker: EKTA B
- Venue: Nasdaq Stockholm
- Price (as of 06/18/2026, 17:30 CET): 48.16 SEK
- Market cap: approximately 18,000,000,000 SEK (as of 06/18/2026)
- Sector / Industry: Health Care / Medical Equipment
- Index membership: OMX Stockholm Benchmark
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
